Applications of Cord Blood Stem Cells
|
|
|
- Norman James
- 6 years ago
- Views:
Transcription
1 Applications of Cord Blood Stem Cells over 360 families have used their banked cord blood in transplant or regenerative medicine research ViaCord has released over 360 units for transplant or infusion to over 60 leading medical institutions. 1 % at 1 year ViaCord publihes the highest transplant survival rates for hematopoietic transplants. 2 Only family cord blood bank to publish short and long-term survival rates. 2l Units Released Transplant (average age of recipient ~6 years old) Oncology 28% Sickle Cell 26% Thalassemia 19% Rare 15% Anemias 12% Transplant 56% 44% Regen Med Regenerative Medicine (average age of recipient ~4 years old) Cerebral Palsy 65% Autism 22% Other 13% Based on 365 units - Data on File. 5-Compartment Storage Bag ViaCord stores cord blood in a multi-compartment bag giving families: More Options: Physicians can access the cells from a single collection in as many as five treatments, or all at once, depending on the medical need. 9 Greater Flexibility: Five compartments maximize the value of cord blood stem cells as we enter into the era of regenerative medicine. 9
2 ViaCord Delivers More Cells Successful transplantation of cord blood stem cells depends primarily on the number of TNCs and CD34+ stem cells collected, processed and cryopreserved. The higher the dose, the greater the chance of transplant success. 5,6 More Cord Blood Stem Cells More stem cells provide superior dosing for transplant/infusion. 5 ViaCord co-developed the only FDA-approved cord blood collection bag, which contains CPD and was designed to collect and preserve more cells. 1,7,8 ViaCord s collection system provides 33% more TNCs and 58% more CD34+ stem cells. 7 The average size of a ViaCord unit released for transplantation is nearly 1 billion TNCs. 1 Sibling Connection Program ViaCord s Sibling Connection program includes cord blood processing and five years of storage at no cost to expecting parents who have a child in need of a transplant. Any expectant family with a child who has an established diagnosis of a disease that is currently treatable with sibling cord blood may be eligible (the newborn must be a full sibling). More info at viacord.com/sibling-connection
3 HEMATOPOIETIC TRANSPLANTS FOR CURRENT TREATMENTS* All transplant recipients were conditioned with chemotherapy/radiation prior to treatment TR Sickle Cell 06/ Sibling TR Sickle Cell 06/ Sibling TR Sickle Cell 05/ Sibling TR DiGeorge Syndrome and Severe 04/ Sibling TR Adrenoleukodystrophy 04/ Sibling TR Chronic Granulomatous Disorder 03/ Sibling TR Thalassemia 01/ Sibling TR Fanconi Anemia 01/ Sibling TR Sickle Cell 12/ Sibling TR Sickle Cell 11/ Sibling TR Diamond Blackfan Aemia 09/ Sibling TR Acute Myelogenous Leukemia 08/ Sibling TR Thalassemia 08/ Sibling TR Thalassemia 07/ Sibling TR Juvenile Myelomonocytic Leukemia 05/ Sibling TR Severe Congenital Neutropenia 02/ Sibling TR Diamond Blackfan Anemia 11/ Sibling TR Sickle Cell 11/ Sibling TR Thalassemia 10/ Sibling TR Severe Congenital Neutropenia 08/ Sibling TR Sickle Cell 07/ Sibling TR Sickle Cell 05/ Sibling TR Diamond Blackfan Anemia 04/ Sibling TR Sickle Cell 04/ Sibling TR Thalassemia 04/ Sibling TR Acute Lymphoblastic Leukemia 04/ Sibling TR Acute Lymphoblastic Leukemia 04/ Sibling TR Acute Myelogenous Leukemia 04/ Autologous (Self) TR Acute Lymphoblastic Leukemia 01/ Sibling TR Sickle Cell 08/ Sibling TR Sickle Cell 08/ Sibling TR Acute Myeloid Leukemia 05/ Sibling TR Severe Combined Immune Deficiency 04/ Sibling TR Sickle Cell 04/ Sibling TR Sickle Cell 04/ Sibling TR Leukemia 03/ Sibling TR Sickle Cell 02/ Sibling TR Chronic Myeloid Leukemia 01/ Sibling TR Sickle Cell 08/ Sibling TR Sickle Cell 07/ Sibling TR Thalassemia 06/ Sibling TR Fanconi Anemia 05/ Sibling TR Chronic Granulomatus 03/ Sibling TR Wiskott-Aldrich Syndrome 02/ Sibling TR Diamond Blackfan Anemia 02/ Sibling TR Juvenile Myelomoncytic Leukemia 01/ Sibling
4 HEMATOPOIETIC TRANSPLANTS FOR CURRENT TREATMENTS* All transplant recipients were conditioned with chemotherapy/radiation prior to treatment TR Thalassemia 09/ Sibling TR Acute Myelogenous Leukemia 07/ Sibling TR Diamond Blackfan Anemia 06/ Sibling TR Thalassemia 04/ Sibling TR Sickle Cell 03/ Sibling TR Sickle Cell 03/ Sibling TR Sickle Cell 03/ Sibling TR Acute Myelogenous Leukemia 02/ Sibling TR Aplastic Anemia 02/ Sibling TR Fanconi Anemia 01/ Sibling TR Fanconi Anemia 01/ Sibling TR Hemophagocytic Lymphohistiocytosis 11/ Autologous (Self) N/A TR Thalassemia 08/ Sibling TR E Beta Thalassemia 07/ Sibling TR E Beta Thalassemia 05/ Sibling TR Acute Myeloid Leukemia 05/ Sibling TR Sickle Cell 03/ Sibling TR Acute Lymphoblastic Leukemia 03/ Sibling TR Sickle Cell 03/ Sibling TR Sickle Cell 02/ Sibling TR Acute Myelogenous Leukemia 09/ Sibling TR Aplasitc Anemia 09/ Sibling TR Sickle Cell 09/ Sibling TR Sickle Cell 09/ Sibling TR Acute Lymphoblastic Leukemia 08/ Sibling TR Sickle Cell 07/ Sibling TR Cartilage-Hair Hypoplasia 07/ Sibling TR Myelodysplastic Syndrome 05/ Autologous (Self) TR Thalassemia 03/ Sibling TR Acute Lymphoblastic Leukemia 12/ Sibling TR Sickle Cell 11/ Sibling TR Acute Myeloid leukemia 10/ Sibling TR Acute Lymphoblastic Leukemia 08/ Sibling TR Sickle Cell 07/ Sibling TR Chronic Granulomatus 07/ Sibling TR Sickle Cell 07/ Sibling TR Sickle Cell 06/ Sibling TR Sickle Cell 06/ Sibling TR Sickle Cell 04/ Sibling TR Fanconi Anemia 04/ Sibling TR Severe Aplastic Anemia 01/ Autologous (Self) TR Non- Hodgkin s Lymphoma 12/ Sibling TR Primative Neuronal Tumor 12/ Autologous (Self) TR Acute Lymphoblastic Leukemia 12/ Sibling TR Sickle Cell 08/ Sibling TR Acute Lymphoblastic Leukemia 08/ Sibling
5 HEMATOPOIETIC TRANSPLANTS FOR CURRENT TREATMENTS* All transplant recipients were conditioned with chemotherapy/radiation prior to treatment TR Acute Myelogenous Leukemia 07/ Sibling TR Sickle Cell 07/ Sibling TR Thalassemia 05/ Sibling TR Thalassemia 05/ Sibling TR Acute Lymphoblastic Leukemia 01/ Sibling TR Thalassemia 12/ Sibling TR Fanconi Anemia 10/ Sibling TR Sickle Cell 10/ Sibling TR Sickle Cell 09/ Sibling TR Sickle Cell 09/ Sibling TR Chronic Granulomatous 06/ Sibling TR Acute Lymphoblastic Leukemia 06/ Sibling TR Severe Aplastic Anemia 06/ Sibling TR Severe Combined Immune Deficiency 06/ Sibling TR Acute Lymphoblastic Leukemia 05/ Sibling TR Sickle Cell 04/ Sibling TR Acute Lymphoblastic Leukemia 04/ Sibling TR Brain Cancer 03/ Autologous (Self) TR Acute Lymphoblastic Leukemia 03/ Sibling TR Thalassemia 02/ Sibling TR Severe Congenital Neutropenia 02/ Sibling TR Acute Myelogenous Leukemia 01/ Sibling TR Sickle Cell 01/ Sibling TR Sickle Cell 01/ Sibling TR Acute Myelogenous Leukemia 12/ Sibling TR Acute Myelogenous Leukemia 10/ Sibling TR Sickle Cell 09/ Sibling TR Thalassemia 08/ Sibling TR Sickle Cell 06/ Sibling TR Sickle Cell 05/ Sibling TR Shwachman-Diamond Anemia 05/ Sibling TR Acute Lymphoblastic Leukemia 05/ Sibling TR Lymphoma 04/ Sibling TR Thalassemia 03/ Sibling TR Myelodysplastic Syndrome 03/ Sibling TR Acute Lymphoblastic Leukemia 01/ Sibling TR Severe Aplastic Anemia 12/ Sibling TR Sickle Cell 10/ Sibling TR Adrenoleukodystrophy 10/ Sibling TR Sickle Cell 09/ Sibling TR Thalassemia 09/ Sibling TR Thalassemia 07/ Sibling TR Sickle Cell 07/ Sibling TR Acute Lymphoblastic Leukemia 06/ Sibling TR Acute Myelogenous Leukemia 05/ Sibling TR Acute Myelogenous Leukemia 03/ Sibling
6 HEMATOPOIETIC TRANSPLANTS FOR CURRENT TREATMENTS* All transplant recipients were conditioned with chemotherapy/radiation prior to treatment TR Kostmann s Syndrome 03/ Sibling TR Thalassemia 03/ Sibling TR Fanconi Anemia 01/ Sibling TR Thalassemia 01/ Sibling TR Thalassemia 01/ Sibling TR Thalassemia 12/ Sibling TR Thalassemia 12/ Sibling TR Thalassemia 11/ Sibling TR Ectodermal Dysplasia 10/ Sibling TR Thalassemia 09/ Sibling TR Thalassemia 08/ Sibling TR Acute Myelogenous Leukemia 02/ Sibling TR Sickle Cell 01/ Sibling TR Acute Lymphoblastic Leukemia 12/ Sibling TR Thalassemia 12/ Sibling TR Hurler Syndrome 11/ Sibling TR Wiskott Aldrich Syndrome 10/ Sibling TR Acute Lymphoblastic Leukemia 09/ Sibling TR Fanconi Anemia 08/ Sibling TR Acute Lymphoblastic Leukemia 08/ Sibling TR Diamond-Blackfan Anemia 08/ Sibling TR Sickle Cell 06/ Sibling TR Acute Lymphoblastic Leukemia 06/ Sibling TR Severe Aplastic Anemia 05/ Sibling TR Acute Lymphoblastic Leukemia 05/ Sibling TR Thalassemia 05/ Sibling TR Acute Myelogenous Leukemia 03/ Sibling TR Acute Lymphoblastic Leukemia 01/ Sibling TR Myelodysplastic Syndrome 01/ Sibling TR Acute Myelogenous Leukemia 12/ Sibling TR Acute Lymphoblastic Leukemia 11/ Sibling TR Sickle Cell 10/ Sibling TR Immune Dysregulation, Polyendocrinopathy, Enteropathy, X-linked Syndrome 09/ Sibling TR Acute Myelogenous Leukemia 08/ Sibling TR Acute Myelogenous Leukemia 07/ Sibling TR Sickle Cell 07/ Sibling TR Acute Myelogenous Leukemia 06/ Sibling TR Chronic Granulomatous 04/ Sibling TR Fanconi Anemia 04/ Sibling TR Thalassemia 02/ Sibling TR Acute Lymphoblastic Leukemia 01/ Sibling TR Neuroblastoma 12/ Autologous (Self) TR Sickle Cell 12/ Sibling TR Thalassemia 11/ Sibling TR Sickle Cell 11/ Sibling TR Acute Lymphoblastic Leukemia 07/ Sibling
7 HEMATOPOIETIC TRANSPLANTS FOR CURRENT TREATMENTS* All transplant recipients were conditioned with chemotherapy/radiation prior to treatment TR Severe Aplastic Anemia 06/ Sibling TR Severe Aplastic Anemia 04/ Autologous (Self) TR Thalassemia 12/ Sibling TR Thalassemia 12/ Sibling TR Acute Myelogenous Leukemia 11/ Sibling TR Severe Aplastic Anemia 10/ Sibling TR Thalassemia 10/ Sibling TR Sickle Cell 07/ Sibling TR Thalassemia 06/ Sibling TR Sickle Cell 05/ Sibling TR Sickle Cell 02/ Sibling CORD BLOOD INFUSIONS FOR REGENERATIVE MEDICINE RESEARCH*** The conditionslisted below are being studied subject to FDA-approved Clinical Trials INF Autism Spectrum Disorder 06/ Autologous (Self) INF Autism Spectrum Disorder 06/ Autologous (Self) INF Autism Spectrum Disorder 05/ Autologous (Self) INF Autism Spectrum Disorder 04/ Autologous (Self) INF Autism Spectrum Disorder 04/ Autologous (Self) INF Autism Spectrum Disorder 04/ Autologous (Self) INF Cerebral Palsy 04/ Autologous (Self) INF Apraxia 03/ Autologous (Self) INF Autism Spectrum Disorder 03/ Autologous (Self) INF Autism Spectrum Disorder 03/ Autologous (Self) INF Cerebral Palsy 01/ Autologous (Self) INF Autism Spectrum Disorder 01/ Autologous (Self) INF Autism Spectrum Disorder 01/ Autologous (Self) INF Autism Spectrum Disorder 01/ Autologous (Self) INF Autism Spectrum Disorder 12/ Autologous (Self) INF Autism Spectrum Disorder 11/ Autologous (Self) INF Autism Spectrum Disorder 11/ Autologous (Self) INF Autism Spectrum Disorder 10/ Autologous (Self) INF Autism Spectrum Disorder 10/ Autologous (Self) INF Autism Spectrum Disorder 10/ Autologous (Self) INF Autism Spectrum Disorder 10/ Autologous (Self) INF Autism Spectrum Disorder 09/ Autologous (Self) INF Autism Spectrum Disorder 09/ Autologous (Self) INF Autism Spectrum Disorder 09/ Autologous (Self) INF Autism Spectrum Disorder 09/ Autologous (Self) INF Autism Spectrum Disorder 06/16 <1 11 Autologous (Self) INF Apraxia 03/ Autologous (Self)
8 CORD BLOOD INFUSIONS FOR REGENERATIVE MEDICINE RESEARCH*** The conditions listed below are being studied subject to FDA-approved Clinical Trials INF Cerebral Palsy 03/ Sibling INF Cerebral Palsy 03/ Sibling INF Cerebral Palsy 03/ Sibling INF Apraxia 03/ Autologous (Self) INF Cerebral Palsy 03/ Sibling INF Apraxia 02/ Autologous (Self) INF Apraxia 01/ Autologous (Self) INF Cerebral Palsy 12/ Sibling INF Cerebral Palsy 09/15 <1 9 Autologous (Self) INF Obstructive Hydrocephalus, Nystgamu and Cerebral Palsy 08/15 <1 10 Autologous (Self) INF Cerebral Palsy 07/ Autologous (Self) INF Cerebral Palsy 01/ Autologous (Self) INF Cerebral Palsy 01/ Autologous (Self) INF Autism Spectrum Disorder 12/ Autologous (Self) INF Autism Spectrum Disorder 12/ Autologous (Self) INF Autism Spectrum Disorder 11/ Autologous (Self) INF Autism Spectrum Disorder 11/ Autologous (Self) INF Autism Spectrum Disorder 11/ Autologous (Self) INF Autism Spectrum Disorder 11/ Autologous (Self) INF Autism Spectrum Disorder 10/ Autologous (Self) N/A INF Cerebral Palsy 10/ Autologous (Self) INF Autism Spectrum Disorder 10/ Autologous (Self) INF Cerebral Palsy 10/ Autologous (Self) INF Autism Spectrum Disorder 09/ Autologous (Self) INF Cerebral Palsy 09/ Autologous (Self) INF Autism Spectrum Disorder 08/ Autologous (Self) INF Autism Spectrum Disorder 07/ Autologous (Self) INF Autism Spectrum Disorder 07/ Autologous (Self) INF Hydrocephalus 04/ Autologous (Self) INF Cerebral Palsy 04/ Autologous (Self) INF Stroke Injury 12/ Autologous (Self) INF Cerebral Palsy 09/ Autologous (Self) INF Cerebral Palsy 07/ Autologous (Self) INF Cerebral Palsy 05/ Autologous (Self) INF Cerebral Palsy 03/ Autoglous (Self) INF Hydrocephalus 03/ Autologous (Self) INF Cerebral Palsy 02/ Autologous (Self) INF Cerebral Palsy 01/ Autologous (Self) INF Cerebral Palsy 01/ Autologous (Self) INF Septic Brain Injury 11/ Autologous (Self) INF Cerebral Palsy 11/ Autologous (Self) N/A INF Cerebral Palsy 10/ Autologous (Self) INF Cerebral Palsy 07/ Autologous (Self) INF Cerebral Palsy 06/ Autologous (Self) INF Cerebral Palsy 06/ Autologous (Self) INF Cerebral Palsy 04/ Autologous (Self)
9 CORD BLOOD INFUSIONS FOR REGENERATIVE MEDICINE RESEARCH*** The conditions listed below are being studied subject to FDA-approved Clinical Trials INF Cerebral Palsy 04/ Autologous (Self) INF Cerebral Palsy 03/ Autologous (Self) INF Cerebral Palsy 03/ Autologous (Self) INF Cerebral Palsy 02/ Autologous (Self) INF Cerebral Palsy 01/ Autologous (Self) INF Cerebral Palsy 12/ Autologous (Self) INF Cerebral Palsy 11/ Autologous (Self) INF Cerebral Palsy 09/ Autologous (Self) INF Cerebral Palsy 09/ Autologous (Self) INF Cerebral Palsy 09/ Autologous (Self) INF Hydrocephalus 09/ Autologous (Self) INF Cerebral Palsy 08/ Autologous (Self) INF Cerebral Palsy 08/ Autologous (Self) INF Cerebral Palsy 07/ Autologous (Self) INF Cerebral Palsy 05/ Autologous (Self) INF Cerebral Palsy 04/ Autologous (Self) INF Cerebral Palsy 04/ Autologous (Self) INF Cerebral Palsy 04/ Autologous (Self) INF Cerebral Palsy 01/ Autologous (Self) INF Cerebral Palsy 01/ Autologous (Self) INF Cerebral Palsy 01/ Autologous (Self) INF Type 1 Diabetes 12/ Autologous (Self) INF Cerebral Palsy 12/ Autologous (Self) INF Cerebral Palsy 11/ Autologous (Self) INF Cerebral Palsy 11/ Autologous (Self) INF Cerebral Palsy 11/ Autologous (Self) INF Cerebral Palsy 11/ Autologous (Self) INF Cerebral Palsy 10/ Autologous (Self) INF Cerebral Palsy 08/ Autologous (Self) INF Cerebral Palsy 07/ Autologous (Self) INF Cerebral Palsy 06/ Autologous (Self) INF Cerebral Palsy 06/ Autologous (Self) INF Hydrocephalus 05/ Autologous (Self) INF Cerebral Palsy 02/ Autologous (Self) INF Cerebral Palsy 01/ Autologous (Self) INF Cerebral Palsy 01/ Autologous (Self) INF Cerebral Palsy 01/ Autologous (Self) INF Type 1 Diabetes 12/ Autologous (Self) N/A INF Cerebral Palsy 12/ Autologous (Self) INF Cerebral Palsy 11/ Autologous (Self) INF Cerebral Palsy 11/ Autologous (Self) INF Cerebral Palsy 11/ Autologous (Self) INF Cerebral Palsy 10/ Autologous (Self) INF Cerebral Palsy 10/ Autologous (Self) N/A INF Cerebral Palsy 09/ Autologous (Self)
10 CORD BLOOD INFUSIONS FOR REGENERATIVE MEDICINE RESEARCH*** The conditions listed below are being studied subject to FDA-approved Clinical Trials INF Cerebral Palsy 09/ Autologous (Self) INF Type 1 Diabetes 09/ Autologous (Self) N/A INF Cerebral Palsy 09/ Autologous (Self) INF Cerebral Palsy 09/ Autologous (Self) INF Cerebral Palsy 09/ Autologous (Self) INF Cerebral Palsy 07/ Autologous (Self) INF Cerebral Palsy 07/ Autologous (Self) INF Cerebral Palsy 07/ Autologous (Self) INF Cerebral Palsy 06/ Autologous (Self) INF Cerebral Palsy 06/ Autologous (Sefl) INF Cerebral Palsy 06/ Autologous (Self) INF Cerebral Palsy 05/ Autologous (Self) INF Cerebral Palsy 04/ Autologous (Self) INF Cerebral Palsy 04/ Autologous (Self) INF Cerebral Palsy 04/ Autologous (Self) INF Cerebral Palsy 03/ Autologous (Self) INF Cerebral Palsy 03/ Autologous (Self) INF Cerebral Palsy 03/ Autologous (Self) INF Cerebral Palsy 02/ Autologous (Self) INF Cerebral Palsy 02/ Autologous (Self) INF Cerebral Palsy 02/ Autologous (Self) N/A INF Cerebral Palsy 02/ Autologous (Self) INF Cerebral Palsy 02/ Autologous (Self) INF Cerebral Palsy 01/ Autologous (Self) N/A INF Cerebral Palsy 01/ Autologous (Self) INF Cerebral Palsy 01/ Autologous (Self) INF Cerebral Palsy 12/ Autologous (Self) INF Cerebral Palsy 12/ Autologous (Self) INF Cerebral Palsy 12/ Autologous (Self) INF Cerebral Palsy 11/ Autologous (Self) INF Cerebral Palsy 09/ Autologous (Self) INF Cerebral Palsy 09/ Autologous (Self) INF Type 1 Diabetes 08/ Autologous (Self) INF Cerebral Palsy 08/ Autologous (Self) INF Cerebral Palsy 07/ Autologous (Self) INF Cerebral Palsy 07/ Autologous (Self) INF Cerebral Palsy 07/ Autologous (Self) INF Traumatic Brain Injury 06/ Autologous (Self) INF Traumatic Brain Injury 06/ Autologous (Self) INF Type 1 Diabetes 03/ Autologous (Self) INF Dysgenesis of the Corpus Callosum 03/ Autologous (Self)
11 For more information visit viacord.com IMPORTANT NOTES This Applications of Cord Blood Stem Cells piece is intended for educational/marketing purposes only and should not be used or interpreted as information on treatments or diagnoses. Infusions For Emerging Research: Cord blood stem cell research to treat these additional diseases is experimental. These diseases are currently not considered treatable with cord blood stem cells and may never be considered effective in treating such diseases. The odds are relatively low that cord blood you elect to store will be used to treat a family member. KEYS Based on the number of family-banked units for transplant and infusion. l Based on available family bank data. 116 of 132 patients treated by January // Overall survival rate. n=156 and total nucleated cell count is 9.79 x 108. Anticoagulant included. TR= transplant INF= infusion. REFERENCES *Banking cord blood does not gaurantee that treatment will work and only a doctor can determine when it can be used. ***Cord blood stem cell infusions for Regenerative Medicine Research is expirimental. These conditions are currently not considererd treatable with cord blood stem cells and may never be considered effective in treating such diseases. 1. Data on File, PerkinElmer, Inc. 2. Walters MC, Edwards S, Robertson S, Falcon K, Briddell R, Lubin B. Sibling donor cord blood transplantation for hemoglobinopathies. Abstract presented at: 8th Annual International Umbilical Cord Blood Transplantation Symposium; June 3-5, 2010; San Francisco, CA. 3. Kraus M, Foster K, Bridges AR, Walters M. Abstract Presented at the 51st American Society of Hematology Annual Meeting and Exposition; New Orleans, LA: December 5-8, Publication # Bridell R, Litkenhaus F, Foertsch G, et al. Isolation of viable MSCs from fresh umbilical cord tissue is on average 8-fold higher after cryopreservation, when compared to isolation of viable MSCs from previously cryopreserved cord tissue segments. Abstract presented to: American Society of Hematology. 5. Rubinstein P, Carrier C, Scaradavou A, Kurtzberg J, et al. Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med. 1998;339(22): Laughlin MJ, Barker J, Bambach B, et al. Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors.n Engl J Med 2001;344(24): Kraus M, Foster K, Bridges AR, Walters MC. Cord blood units collected with liquid CPD appear to contain significantly more nucleated and CD34+ cells than units collected with dry heparin. Study conducted by ViaCord. Paper presented at: 51st American Society of Hematology Annual Meeting and Exposition; December 5-8, 2009; New Orleans, LA. Abstract Center for Biologics Evaluation and Research, Food and Drug Administration, US Department of Health and Human Services. Guidance for industry: minimally manipulated, unrelated allogeneic placental/umbilical cord blood intended for hematopoietic reconstitution for specified indications. guidancecomplianceregulatoryinformation/guidances/blood/ucm pdf. October Accessed November 21, Driscoll, Kimberly A., Suzanne Bennett Johnson, Desmond A. Schatz, and Michael J. Haller. Use of a Precious Resource: Parental Decision Making about Using Autologous Umbilical Cord Blood in Studies Involving Young Children with Type 1 Diabetes. Contemporary Clinical Trials 32.4 (2011): ViaCord All Rights Reserved. BRO-TXSUM-0817
No Other Company Discloses Higher Transplant Survival Rate. Infusions For Emerging Treatments. Date of Use. Recipient Age (yrs)
Units Used In Transplants/Infusions No Other Company Discloses Higher Transplant Survival Rate Family Banking Provides Exclusive Access To Emerging Treatments With Your Own Cells 175 85% Type 1 Diabetes
What are stem cells? A stem cell can differentiate into any one of 220 different specialised cells in the body STEM CELLS
What are stem cells? Stem cells are often called MASTER CELLS, and form the foundation for your entire body as building blocks for the blood, immune system, tissue and organs. They can REPLICATE or REGENERATE
Recommended Timing for Transplant Consultation
REFERRAL GUIDELINES Recommended Timing for Transplant Consultation Published jointly by the National Marrow Donor Program /Be The Match and the American Society for Blood and Marrow Transplantation BeTheMatchClinical.org
Standard Therapies - Cord Blood
A healthy future is in your hands 01 02 03 04 Standard Therapies - Cord Blood Clinical Trials with Blood - Forming Stem Cells Gene Therapy for Inherited Disorders Using Blood - Forming Stem Cells Clinical
HEMATOPOIETIC CELL TRANSPLANTATION FOR GENETIC DISEASES AND ACQUIRED ANEMIAS
ACQUIRED ANEMIAS Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs are
INFORMATION KIT H PE. IS IN YOUR NEWBORN S BLOOD Help it last a lifetime with cord blood banking. Save $300 with Promo Code.
INFORMATION KIT H PE IS IN YOUR NEWBORN S BLOOD Help it last a lifetime with cord blood banking Save $300 with Promo Code Cord4Life CORD BLOOD STEM CELLS Umbilical cord blood is unique and is only available
STEMCYTE INDIA s impeccable transplant record (Unmatched in Cord Blood industry)
STEMCYTE INDIA s impeccable transplant record (Unmatched in Cord Blood industry) 1 1 No. Patient Name Diseases Transplant Centers Cord Blood Volume in ml 1 Patient 1 RELAPSED BILINEAGE LEUKEMIA HLA match
a resource for physicians Recommended Referral Timing for Stem Cell Transplant Evaluation
a resource for physicians Recommended Referral Timing for Stem Cell Transplant Evaluation This resource has been developed to help guide you regarding the appropriate timing and conditions for a referral
Donating your baby s cord to a public cord blood bank can save lives globally.
Donating your baby s cord to a public cord blood bank can save lives globally. You can play an important role in saving lives by donating the blood contained in your baby s umbilical cord to LifeCord,
Corporate Medical Policy
Corporate Medical Policy Allogeneic Hematopoietic Transplant for Genetic Diseases and File Name: Origination: Last CAP Review: Next CAP Review: Last Review: allogeneic_hematopoietic_transplant_for_genetic_diseases
Hematopoietic Stem Cell Therapy
Hematopoietic Stem Cell Therapy Grace Totoe, MBChB, SBB CME August 2012 Accra-Ghana Hematopoietic Stem Cells Cells capable of self renewal and differentiation into all blood cell lineages Objectives Historical
Leukine. Leukine (sargramostim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Leukine Page: 1 of 6 Last Review Date: November 30, 2018 Leukine Description Leukine (sargramostim)
Give Birth to Hope: An Unique Approach to Public Cord Blood Donation
Give Birth to Hope: An Unique Approach to Public Cord Blood Donation The Public Health Nursing and Professional Development Unit, North Carolina Division of Public Health, is approved as a provider of
BMTCN Review Course Basic Concepts and Indications for Transplantation How the Experts Treat Hematologic Malignancies Las Vegas, NV, March 10, 2016
BMTCN Review Course Basic Concepts and Indications for Transplantation How the Experts Treat Hematologic Malignancies Las Vegas, NV, March 10, 2016 David Rice, PhD, RN, NP Director, Professional Practice
Family Medical History Questionnaire (FMHQ)
First, Last Name DOB: Cord Blood Bank Use Only: Family Medical History Questionnaire (FMHQ) NMDP CBU ID: Local CBU ID: NMDP Maternal ID: Today's Date: Local Maternal ID: Baby's Mother's Initials: Please
Experts balk at large trial of stem cells for autism
NEWS Experts balk at large trial of stem cells for autism BY NIDHI SUBBARAMAN 14 JULY 2014 1 / 5 Cold comfort: Researchers are trying to find out whether stem cells taken from frozen cord blood can improve
Stem cells. -Dr Dinesh Bhurani, MD, DM, FRCPA. Rajiv Gandhi Cancer Institute, Delhi, -Director, Department of Haematology and BMT
Stem cells -Dr Dinesh Bhurani, MD, DM, FRCPA -Director, Department of Haematology and BMT Rajiv Gandhi Cancer Institute, Delhi, Flow of presentation Update on stem cell uses Haematopoietic stem cell transplantation
Cord Blood Stem Cell Banking and Transplantation
Cord Blood Stem Cell Banking and Transplantation JOHN W. ADAMSON New York Blood Center, New York, New York, USA Key Words. Cord blood Stem cells Cord blood banking Cord blood transplantation. Cord blood.stern
Bin them or bank them?
Bin them or bank them? What are stem cells? Single cells that can Differentiate into any one of 220 different specialised cells in the body or......replicate themselves Stem cells are often called master
BMTCN Review Course Basic Concepts and Indications for Transplantation. David Rice, PhD, RN, NP
BMTCN Review Course Basic Concepts and Indications for Transplantation March 16, 2017 David Rice, PhD, RN, NP Director, Professional Practice and Education No disclosures Objectives Describe basic concepts
Cord Blood Bankers are. Angie Yost, MT(ASCP) CM 2016 ASCLS-MO CLMA Spring Meeting
Cord Blood Bankers are Angie Yost, MT(ASCP) CM 2016 ASCLS-MO CLMA Spring Meeting Objectives Cord blood 101 Manufacturing and cryopreservation Characterization testing Why Do We Need Cord Blood? Each year,
A GLOBAL REGENERATIVE THERAPEUTICS COMPANY. A Commitment to EXCELLENCE. IMPECCABLE TRANSPLANT RECORD Unmatched in cord blood industry
A GLOBAL REGENERATIVE THERAPEUTICS COMPANY A Commitment to EXCELLENCE IMPECCABLE TRANSPLANT RECORD Unmatched in cord blood industry IT HAPPENS ONLY IN STEMCYTE A GLOBAL REGENERATIVE THERAPEUTICS COMPANY
Pediatric Hematopoietic Stem Cell Transplantation. Meng Yao Lu/ Kai Hsin Lin Department of Pediatrics National Taiwan University Hospital
Pediatric Hematopoietic Stem Cell Transplantation Meng Yao Lu/ Kai Hsin Lin Department of Pediatrics National Taiwan University Hospital Outline Overview Indication Stem cell source New revolution Cord
Hematopoiesis i starts from. HPC differentiates t to sequentially more mature. HPC circulate in very low
Upstate Cord Blood Bank Hematopoietic Progenitor Cells Hematopoiesis i starts from self renewing HPC HPC differentiates t to sequentially more mature blood cells HPC circulate in very low numbers in adults
SECOND ANNUAL INTERNATIONAL UMBILICAL CORD BLOOD SYMPOSIUM
Biology of Blood and Marrow Transplantation 10:728-739 (2004) 2004 American Society for Blood and Marrow Transplantation 1083-8791/04/1010-0009$30.00/0 doi:10.1016/j.bbmt.2004.06.010 SECOND ANNUAL INTERNATIONAL
Leukine. Leukine (sargramostim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.08 Subject: Leukine Page: 1 of 5 Last Review Date: September 15, 2017 Leukine Description Leukine
Stem cell applications- Cord blood, Cord tissue, Fat tissue
Stem cell applications- Cord blood, Cord tissue, Fat tissue Annual General Meeting of Shareholders 18 May 2011 Arnoud van Tulder Chief Executive Officer 1 Latest news about stem cells (1/3) New heartwithownstem
Regence. Next Review: 08/2019 Last Review: 08/2018 Medicare Link(s) Revised: 10/01/2018 IMPORTANT REMINDER
Regence Medicare Advantage Policy Manual Policy ID: M-TRA45 Stem Cell / Bone Marrow Transplants Published: 10/01/2018 Next Review: 08/2019 Last Review: 08/2018 Medicare Link(s) Revised: 10/01/2018 IMPORTANT
Medical Policy. MP Placental and Umbilical Cord Blood as a Source of Stem Cells
Medical Policy MP 7.01.50 BCBSA Ref. Policy: 7.01.50 Last Review: 01/30/2018 Effective Date: 01/30/2018 Section: Surgery Related Policies 8.01.20 Hematopoietic Cell Transplantation for Non- Hodgkin Lymphomas
Stem Cell Transplantation for Severe Aplastic Anemia
Number of Transplants 10/24/2011 Stem Cell Transplantation for Severe Aplastic Anemia Claudio Anasetti, MD Professor of Oncology and Medicine Chair, Blood and Marrow Transplant Dpt Moffitt Cancer Center
Clinical Policy: Donor Lymphocyte Infusion
Clinical Policy: Reference Number: PA.CP.MP.101 Effective Date: 01/18 Last Review Date: 11/16 Coding Implications Revision Log This policy describes the medical necessity requirements for a donor lymphocyte
Blood & Marrow Transplantation Center
Blood & Marrow Transplantation Center We were one of the first centers in the world to routinely offer patients blood and marrow transplantation (BMT). What Sets Us Apart High-volume center performs about
Placental and Umbilical Cord Blood as a Source of Stem Cells
Placental and Umbilical Cord Blood as a Source of Stem Cells Policy Number: 7.01.50 Last Review: 12/2018 Origination: 12/2001 Next Review: 12/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue
July 3, The Physician Compare Team Centers for Medicare and Medicaid Services 7500 Security Boulevard Baltimore, MD 21244
July 3, 2013 The Physician Compare Team Centers for Medicare and Medicaid Services 7500 Security Boulevard Baltimore, MD 21244 Re: Physician Compare Intelligent Search To Whom it May Concern, The American
Stem Cells And The Future of Regenerative Medicine. Dipnarine Maharaj, M. D., FACP
Stem Cells And The Future of Regenerative Medicine Dipnarine Maharaj, M. D., FACP The following potential conflict of interest relationships are germane to my presentation. Employment: South Florida Bone
Dr.PSRK.Sastry MD, ECMO
Peripheral blood stem cell transplantation (Haematopoietic stem cell transplantation) Dr.PSRK.Sastry MD, ECMO Consultant, Medical Oncology Kokilaben Dhirubhai Ambani Hospital Normal hematopoiesis Historical
DEPARTMENT OF CLINICAL HEMATOLOGY
DEPARTMENT OF CLINICAL HEMATOLOGY What is blood? Blood is the vital fluid of the body, which performs diverse functions from delivering oxygen to each and every cell of the body to fighting against infections
An Overview of Blood and Marrow Transplantation
An Overview of Blood and Marrow Transplantation October 24, 2009 Stephen Couban Department of Medicine Dalhousie University Objectives What are the types of blood and marrow transplantation? Who may benefit
Topics and Controversies in Newborn Stem Cell Medicine
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
Pediatric Hematology-Oncology
Pediatric Hematology-Oncology Content Outline In-Training, Initial Certification, and Maintenance of Certification Exams Effective for exams administered beginning April 1, 2019 THE AMERICAN BOARD of PEDIATRICS
Hematopoietic Stem Cell Transplant in Sickle Cell Disease- An update
Hematopoietic Stem Cell Transplant in Sickle Cell Disease- An update Dr Chirag A Shah Diplomate American Board of Hematology and Medical Oncology Director, Dept of Hemato-Oncology and Stem Cell Transplant
Leukine. Leukine (sargramostim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.10.08 Subject: Leukine Page: 1 of 6 Last Review Date: March 13, 2014 Leukine Description Leukine (sargramostim)
2/26/2016. Types of Stem Cells: Agenda. Objectives
PAMET, March 5, 2016 Umbilical Cord Blood for Public Banking and Research Regenerative Medicine: Curing disease by repairing or replacing organs and systems through cellular and tissue engineering Bladder
ACGME Program Requirements for Graduate Medical Education in Pediatric Hematology-Oncology
ACGME Program Requirements for Graduate Medical Education in Pediatric Hematology-Oncology ACGME approved: June 27, 2006; effective: July 1, 2007 ACGME approved focused revision: September 30, 2012; effective:
Haematopoietic stem cell transplantation (SCT)
HAEMATOPOIETIC TEM CELL TRANPLANTATION FOR CHILREN IN BELGIUM Marie-Françoise resse 1 & Yves Beguin 2 1 epartment of Paediatrics, ivision of Hemato-Oncology, UHOPL, University of Liege, Liège, Belgium;
Clinical Use of Umbilical Cord Blood Hematopoietic Stem Cells
Biology of Blood and Marrow Transplantation 12:34-41 (2006) 2006 American Society for Blood and Marrow Transplantation 1083-8791/06/1201-0107$32.00/0 doi:10.1016/j.bbmt.2005.09.006 Clinical Use of Umbilical
Company Overview. Investor Presentation. August 2018
Company Overview Investor Presentation August 2018 1 Notice to Investors The sole purpose of this Presentation (this Presentation ) is to assist recipients in deciding whether to proceed with a further
Potency & Release Testing for unrelated donor cord blood units
Potency & Release Testing for unrelated donor cord blood units Joanne Kurtzberg, MD Robertson Cell and Translational Therapy Program Pediatric Blood and Marrow Transplant Program Carolinas Cord Blood Bank
Hematopoetic Stem Cell Therapies in TURKIYE
Hematopoetic Stem Cell Therapies in TURKIYE World Location of transplant centers participating in CIBMTR (2010) Dr. Mustafa ÇETİN Mustafa CETIN, M.D. Erciyes University Medical Faculty Kayseri-TURKIYE
Cord Blood Banking. The Birth of a New Field
FEATURE Karen Titus Cord Blood Banking The Birth of a New Field iven the great availability of cord blood every new birth represents a possible source it's little wonder this blood product has drawn intense
Understanding the role of ex vivo T cell depletion
Prevention of graftversus-host disease (GVHD) Understanding the role of ex vivo T cell depletion Information for patients undergoing allogeneic stem cell transplantation in AML and their families 2 This
ASPHO 2019 Review Course January 31-February 2, 2019
ASPHO 2019 Review Course January 31-February 2, 2019 ABP Content Outline Topics by Date and Speaker For additional information, see the ABP Content Outline and the ABP Content Outline with Speaker Assignments.
Table of Contents. 1.0 Description of the Procedure, Product, or Service... 1
Allogeneic Hematopoietic & Bone Clinical Coverage Policy No: 11A-5 Marrow Transplant for Genetic Amended Date: October 1, 2015 Diseases and Acquired Anemias Table of Contents 1.0 Description of the Procedure,
PGD: FROM DIAGNOSIS TO THERAPY
PGD: FROM DIAGNOSIS TO THERAPY MC Magli, L. Gianaroli Reproductive Medicine Unit - Via Mazzini, 2-438 Bologna www.sismer.it Since the birth of the first baby conceived using IVF techniques in 978 over
Pediatric Hematopoietic Stem Cell Transplant - Experience of an Indian Tertiary Care Center
Pediatric Hematopoietic Stem Cell Transplant - Experience of an Indian Tertiary Care Center Dr Chirag A Shah Diplomate American Board of Hematology and Medical Oncology Director, Dept of Hemato-Oncology
Progenics Cord Blood Cryobank Monthly Quality Report
Progenics Cord Blood Cryobank Monthly Quality Report 2017 Company Profile Progenics Cord Blood Cryobank is a leader in delivering consistent, high quality cord blood processing results, with over 10 years
Sickle Cell Diseasechronic. curable disease? Objectives. Why would a family ask about cure for SCD?
Sickle Cell Diseasechronic illness or curable disease? Gregory M.T. Guilcher MD, FRCPC, FAAP Objectives To review the general principles of hematopoietic stem cell transplantation (HSCT), including risks
THIRD ANNUAL INTERNATIONAL UMBILICAL CORD BLOOD TRANSPLANTATION SYMPOSIUM
Biology of Blood and Marrow Transplantation 11:921-927 (2005) 2005 American Society for Blood and Marrow Transplantation 1083-8791/05/1111-0009$30.00/0 doi:10.1016/j.bbmt.2005.08.028 THIRD ANNUAL INTERNATIONAL
Study for the improvement of umbilical cord blood sampling using a new trial apparatus
bs_bs_banner doi:10.1111/jog.12179 J. Obstet. Gynaecol. Res. Vol. 40, No. 2: 405 409, February 2014 Study for the improvement of umbilical cord blood sampling using a new trial apparatus Naoki Masaoka
AETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Colony Stimulating Factor (CSF)
AETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Colony Stimulating Factor (CSF) Colony Stimulating Factor (CSF) Neupogen (filgrastim; G-CSF), Neulasta (peg-filgrastim; G-CSF); Neulasa
YEREVAN STATE MEDICAL UNIVERSITY DEPARTMENT OF HEMATOLOGY COURSE DESCRIPTION HEMATOLOGY
1. Module/unit Code II. 1.2. 2. Module/unit Title Hematology 3. Subject Field Internal Diseases Group 4. Faculty/Department General Medicine, Department of Hematology 5. Programme(s) to which the Doctor
a d u lt s t e m c e l l t r a n s p l a n tat i o n p r o g r a m i n f o r m at i o n f o r pay e r s a n d r e f e r r e r s
a d u lt s t e m c e l l t r a n s p l a n tat i o n p r o g r a m i n f o r m at i o n f o r pay e r s a n d r e f e r r e r s Summer 2017 For more information, visit www.dfbwcc.org/bmt. o u r expertise
OneMatch Stem Cell and Marrow Network. Training Guide
OneMatch Stem Cell and Marrow Network Training Guide What is OneMatch all about? OneMatch is a Canadian Program that matches and coordinates the collection of stem cells from potential donors to help save
HEMATOPOIETIC ENGRAFTMENT IN ADULT RECIPIENTS OF UMBILICAL-CORD BLOOD FROM UNRELATED DONORS
HEMATOPOIETIC ENGRAFTMENT IN ADULT RECIPIENTS OF UMBILICAL-CORD BLOOD FROM UNRELATED DONORS HEMATOPOIETIC ENGRAFTMENT AND SURVIVAL IN ADULT RECIPIENTS OF UMBILICAL-CORD BLOOD FROM UNRELATED DONORS MARY
DEPARTMENT OF BONE MARROW AND STEM CELL TRANSPLANT
DEPARTMENT OF BONE MARROW AND STEM CELL TRANSPLANT DEPARTMENT OF BONE MARROW TRANSPLANT About Narayana Health City Headquartered in Bangalore, Narayana Health has a network of hospitals across India witha
Protocol Number: 10-CBA National Clinical Trial (NCT) Identified Number: NCT
A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) for transplantation in pediatric and adult patients with hematologic malignancies and other indications
The primary medical content categories of the blueprint are shown below, with the percentage assigned to each for a typical exam:
Hematology Certification Examination Blueprint Purpose of the exam The exam is designed to evaluate the knowledge, diagnostic reasoning, and clinical judgment skills expected of the certified hematologist
POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
Original Issue Date (Created): October 1, 2014 Most Recent Review Date (Revised): May 20, 2014 Effective Date: October 1, 2014 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT
GUIDELINES FOR IRRADIATED BLOOD COMPONENTS
GUIDELINES FOR IRRADIATED BLOOD COMPONENTS 1. Policy Statement 2. Definitions 1.1 Blood transfusion services shall have a policy which indicates recipients who are to receive irradiated blood components.
Cord blood transplantation and stem cell regenerative potential
Experimental Hematology 2011;39:393 412 Cord blood transplantation and stem cell regenerative potential Yanling Liao a, Mark B. Geyer a, Albert J. Yang a, and Mitchell S. Cairo a,b,c a Department of Pediatrics,
Allogeneic Hematopoietic Cell Transplantation for Genetic Diseases and Acquired Anemias
Allogeneic Hematopoietic Cell Transplantation for Genetic Diseases and Acquired Anemias Policy Number: Original Effective Date: MM.07.001 04/01/2008 Line(s) of Business: Current Effective Date: HMO; PPO
2. Is therapy prescribed by, or in consultation with, a hematologist and/or oncologist?
Pharmacy Prior Authorization AETA BETTER HEALTH EW JERSE (MEDICAID) Colony Stimulating Factors (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review
MP Allogeneic Hematopoietic Cell Transplantation for Genetic Diseases and Acquired Anemias
Medical Policy MP 8.01.22 BCBSA ef. Policy: 8.01.22 Last eview: 01/30/2018 Effective Date: 01/30/2018 Section: Therapy elated Policies 8.01.25 Hematopoietic Cell Transplantation for Autoimmune Diseases
Blood and Marrow Transplant (BMT) for Sickle Cell Disease
Blood and Marrow Transplant (BMT) for Sickle Cell Disease Rhiannon is now cured of sickle cell disease after BMT. Blood and marrow transplant (BMT) is a proven cure for sickle cell disease. This handbook
Summary of Changes Page BMT CTN 1205 Protocol Amendment #4 (Version 5.0) Dated July 22, 2016
Page 1 of 8 Date: July 22, 2016 Summary of Changes Page BMT CTN 1205 Protocol #4 Dated July 22, 2016 The following changes, and the rationale for the changes, were made to the attached protocol in this
The role of HLA in Allogeneic Hematopoietic Stem Cell Transplantation and Platelet Refractoriness.
The role of HLA in Allogeneic Hematopoietic Stem Cell Transplantation and Platelet Refractoriness. Robert Liwski, MD, PhD, FRCPC Medical Director HLA Typing Laboratory Department of Pathology Dalhousie
Granix. Granix (tbo-filgrastim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.10.16 Section: Prescription Drugs Effective Date: April 1, 2014 Subject: Granix 1 of 7 Last Review Date:
12 Dynamic Interactions between Hematopoietic Stem and Progenitor Cells and the Bone Marrow: Current Biology of Stem Cell Homing and Mobilization
Table of Contents: PART I: Molecular and Cellular Basis of Hematology 1 Anatomy and Pathophysiology of the Gene 2 Genomic Approaches to Hematology 3 Regulation of Gene Expression, Transcription, Splicing,
DEPARTMENT OF BONE MARROW AND STEM CELL TRANSPLANT
DEPARTMENT OF BONE MARROW AND STEM CELL TRANSPLANT DEPARTMENT OF BONE MARROW TRANSPLANT About Narayana Health City Narayana Health, one of India's largest and the world's most economical healthcare service
Summary of Changes BMT CTN 1101 Version 7.0 to 8.0 Dated: January 18, Original text: Changed to: Rationale
BMT CTN 1101 RIC ducb vs. Haplo Page 1 of 10 Date: January 20, 2017 Summary of Changes BMT CTN 1101 Version 7.0 to 8.0 Dated: January 18, 2017 A Multi-Center, Phase III, Randomized Trial of Reduced Intensity(RIC)
Index. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Acute lymphoblastic leukemia, in India, 439 440 pediatric, global approach to, 420 424 core resources in low- and middle-income countries, 423
The American Society of Hematology (ASH) represents more than 17,000 clinicians and
American Society of Hematology Statement to the House Appropriations Subcommittee on Labor, HHS, Education, and Related Agencies FY 2020 Funding for NIH and CDC The American Society of Hematology (ASH)
Granix. Granix (tbo-filgrastim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.16 Subject: Granix 1 of 7 Last Review Date: December 2, 2016 Granix Description Granix (tbo-filgrastim)
The Blood & Marrow Transplantation Center
The Blood & Marrow Transplantation Center We were one of the first centers in the world to routinely offer patients blood and marrow transplantation (BMT). What Sets Us Apart High-volume center performs
Allogeneic Hematopoietic Cell Transplantation for Genetic Diseases and Acquired Anemias
Medical Policy Manual Transplant, Policy No. 45.25 Allogeneic Hematopoietic Cell Transplantation for Genetic Diseases and Acquired Anemias Next eview: January 2019 Last eview: February 2018 Effective:
& 2007 Nature Publishing Group All rights reserved /07 $
() 9, & Nature Publishing Group All rights reserved 8-9/ $. www.nature.com/bmt ORIGINAL ARTICLE The impact of post-thaw colony-forming units-granulocyte/macrophage on engraftment following unrelated cord
GVHD. URD unrelated donor
1 GVHD T-B GVHD 1 RDrelated donor URDunrelated donor 2. Julie M. Vose and Steven Z. Pavletic. Haematopoietic Stem Cell Transplantation. In Goldman: Cecil Medicine, 23 rd ed.; chapter 184 (Saunders, An
Clinical Policy Title: Bone marrow transplants for cancer (other than breast cancer)
Clinical Policy Title: Bone marrow transplants for cancer (other than breast cancer) Clinical Policy Number: 14.02.06 Effective Date: January 1, 2016 Initial Review Date: November 18, 2015 Most Recent
Expanding Uses of Umbilical Cord Blood: Duke Experience. Vinod K. Prasad, MD, MRCP (London) PBMT Division, Duke University Medical Center
Expanding Uses of Umbilical ord Blood: Duke Experience Vinod K. Prasad, MD, MRP (London) PBMT Division, Duke University Medical enter UBT - Record Umbilical cord blood contains sufficient numbers of stem
Company Overview. January 2019
Company Overview January 2019 1 Disclaimer This Presentation includes certain projections and forward-looking statements as of the date of this Presentation provided by Gamida Cell Ltd (the Company ).
Allogeneic Hematopoietic Stem-Cell Transplantation for Genetic Diseases and Acquired Anemias
Allogeneic Hematopoietic Stem-Cell Transplantation for Genetic Diseases and Acquired Anemias Policy Number: 8.01.22 Last Review: 7/2014 Origination: 7/2002 Next Review: 7/2015 Policy Blue Cross and Blue
LCD for Sargramostim (GM-CSF, Leukine ) (L29275)
LCD for Sargramostim (GM-CSF, Leukine ) (L29275) Contractor Information Contractor Name First Coast Service Options, Inc. Contractor Number 09102 Contractor Type MAC - Part B LCD ID Number L29275 LCD Information
Granix. Granix (tbo-filgrastim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.16 Subject: Granix 1 of 6 Last Review Date: September 15, 2017 Granix Description Granix (tbo-filgrastim)
Hematopoietic Stem Cells
Hematopoietic Stem Cells, Stem Cell Processing, and Joseph (Yossi) Schwartz, M irector, Hemotherapy and Stem Cell Processing Facility E-mail: js2745@columbia.edu Hematopoietic Stem Cells Sustain hematopoiesis
anemias: the current situation
Bone Marrow transplantation in rare anemias: the current situation Dr. Daria Pagliara, MD Pediatric Onco Haematology Department Ospedale Pediatrico Bambino Gesù, Rome 4th European Symposium on Rare Anaemias
Haplo vs Cord vs URD Debate
3rd Annual ASBMT Regional Conference for NPs, PAs and Fellows Haplo vs Cord vs URD Debate Claudio G. Brunstein Associate Professor University of Minnesota Medical School Take home message Finding a donor
Granix. Granix (tbo-filgrastim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.10.16 Subject: Granix 1 of 7 Last Review Date: September 18, 2015 Granix Description Granix (tbo-filgrastim)
Evaluation of Early Post-transplant Leukocyte Recovery Using the Undiluted Erythrocyte Lysing Technique
Annals of Clinical & Laboratory Science, vol. 32, no. 2, 2002 159 Evaluation of Early Post-transplant Leukocyte Recovery Using the Undiluted Erythrocyte Lysing Technique Myungshin Kim, 1 Ja Young Kim,
AETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Colony Stimulating Factor (CSF)
AETNA BETTER HEALTH Non-Formulary Prior Authorization guideline for Colony Stimulating Factor (CSF) Colony Stimulating Factor (CSF) Neupogen (filgrastim; G-CSF), Neulasta (peg-filgrastim; G-CSF); Neulasa